Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Japanese phase 3 study of subcutaneous icatibant for acute hereditary angioedema attacks
jRCT2041200073Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Number of participants who experience at least one treatment-emergent adverse event and Number of participants with injection site reactions. Started Jan 2021; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2041200073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200073.